Dr. Kishore R. Alugupalli, PhD
Founder & CEO TurboVax Inc
Prior to becoming the CEO, Dr. Alugupalli was on the professorial faculty at the University of Massachusetts Medical School, Worcester, MA and Thomas Jefferson University, Philadelphia, PA for more than 20 years. Dr. Alugupalli's expertise includes bacteria and host cell interactions with emphasis on protective B cell responses, formulation of mono & multivalent as well as combination vaccines, development of effective adjuvants based on fundamental scientific principles, and testing vaccine efficacies in innovative preclinical models.
Scientific Advisory Board
Dr. Tasuku Honjo, MD PhD
Deputy Director-General and Distinguished Professor
Institute for Advanced Study, Kyoto University, Japan
Nobel Prize in Physiology or Medicine in 2018
Dr. Honjo is well known for his discovery of activation-induced cytidine deaminase (AID) that is essential for the antibody class switch recombination and somatic hypermutation. Dr. Honjo discovered PD-1 (program cell death 1), a negative coreceptor at the effector phase of immune response and demonstrated that PD-1 inhibition contributes to cancer treatments. Anti-PD-1 cancer immunotherapy is highly effective has been approved in US, EU, and Japan to treat various cancers. This work lead to his Nobel Prize in Physiology or Medicine in 2018.
Dr. Andreas Bäumler, PhD
Professor and Vice Chair of Medical Microbiology and Immunology
University of California School of Medicine, Davis, CA
Dr. Bäumler’s research program investigates mechanisms of intestinal colonization and the host response to Salmonella infection. Dr. Bäumler is an elected member of the American Academy of Microbiology, the German National Academy of Sciences, the United States National Academy of Sciences, and American Association for the Advancement of Science. Won the prestigious Robert Koch prize in 2021 for his outstanding work in bacterial pathogenesis, how our own gut microbiome works and host defense mechanisms.
Dr. Dieter Schifferli, DVM, PhD
Professor of Microbiology Emeritus
University of Pennsylvania, Philadelphia, PA
Over 40 years of experience in bacterial pathogenesis, with emphasis on bacterial ligands that bind to specific host receptors and mediate bacterial colonization, host cell signaling, and/or optimal toxin delivery. Dr Schifferli also focuses his research on vaccines based on bacterial adhesisns to prevent infections caused by human and veterinary bacterial pathogens.
Dr. Katherine Fitzgerald, PhD
Professor and Vice Chair of Medicine
UMass Chan Medical School, Worcester, MA
Chief of the Division of Innate Immunity. Dr. Fitzgerald's work is focused on the innate immune system aimed at understanding the molecular basis of the inflammatory response during Infection and in inflammatory diseases. Her work has a major impact on our current understanding on how immune system works. Dr. Fitzgerald is an elected member of the American Society of Microbiology, the Royal Irish Academy, and the United States National Academy of Sciences.
Board of Advisors
Dr. Stephen J. McGeady, MD
Pediatrician and Physician Scientist
Nemours Children's Health, Philadelphia, PA
A highly accomplished, board-certified and practicing pediatrician with over 50 years experience in treating children with primary immune deficiencies, impaired vaccine responses, and allergy. As a physician scientist identified many genetic abnormalities in children with altered immune responses that paved our understanding of many childhood diseases.
Dr. Gordon Dougan, PhD, FRS
Professor, Department of Medicine, University of Cambridge, United Kingdom
Board member Wellcome Sanger Institute, Cambridge, United Kingdom
Dr. Dougan has pioneered work on enteric diseases and been heavily involved in the movement to improve vaccine usage in developing countries. In this regard he was voted as one of the top ten most influential people in the vaccine world by people working in the area. Dr. Dougan is a trustee of the International Vaccine Institute, Korea and has worked with other global agencies including the World Health Organization and the Global Alliance for Vaccine and Innovations (now GAVI Alliance). Dr. Dougan is an elected member of the European Molecular Biology Organization, Fellow of the Academy of Medical Sciences and Fellow of the Royal Society.
Dr. Rajesh K. Gupta, PhD
CEO, Biologics Quality & Regulatory Consultants LLC
Gaithersburg, MD, USA
Over 40 years’ experience in the development, production, testing, and regulation of vaccines. At FDA, he formed the Division of Biological Standards and Quality Control and was a Deputy Director and Lab Chief in that Division, managing lot release of biological products, review of analytical methods for the biologics license applications, generation of reference standards and development of new methods. He worked at Wyeth, Chiron, FDA & NIH.
Scotty McConnaughey
Portfolio Manager & Senior Equity Research Analyst Cambridge Trust Company
Graduated from Darthmouth College and Harvard University. For over 20 years analyzed stocks and managed equity portfolios for Fidelity Investments, Westfeild Capital Management,. Served as the Investment Director, U.S. Equities for Aberdeen Standard Investments. Served as operating partner for Ouroboros Group and Limited Partner for Six Trees Capital LLC. An accomplished investor with demonstrated history of generating alpha, fostering effective teams, and leading cross-functional projects.
Collaborators
